Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1585-1592

  Wang, Hui ^a,b   Rayburn, Elizabeth R ^a   Wang, Wei ^a   Kandimalla, Ekambar R ^d   Agrawal, Sudhir ^d   Zhang, Ruiwen ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; IMMUNOMODULATING AGENT; MESSENGER RNA; OLIGONUCLEOTIDE; PEMETREXED; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIZATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG TOLERANCE; FEMALE; GLUTAMATES; GUANINE; HUMANS; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDES; RNA, MESSENGER; TOLL-LIKE RECEPTOR 9; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746092105     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0094     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts and figures 2005. Atlanta (GA): American Cancer Society; 2005. Available from:http://www.cancer.org/ docroot/stt/stt_O.asp.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-85.
3. Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 2000;29:91-104.
4. Maziak DE, Markman BR, MacKay JA, Evans WK. Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 2004;77:1484-91.
5. Ferreira CG, Huisman C, Giaccone G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002;41:57-77.
6. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
7. Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 2005;128:2933-43.
8. Natale R. A ten-year review of progress in the treatment of non-small cell lung cancer with gemcitabine. Lung Cancer 2005;50 Suppl 1:S2-4.
9. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005;128:3975-84.
10. Wang H, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogues as novel anticancer therapeutics. Curr Pharm Des 2005;11:2889-907.
11. Sabroe I, Parker LC, Wilson AG, Whyte MK, Dower SK. Toll-like receptors: their role in allergy and non-allergic inflammatory disease. Clin Exp Allergy 2002;32:984-9.
12. Van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999;104:902-10.
13. Dalpke A, Zimmermann S, Heeg K. CpG DNA in the prevention and treatment of infections. BioDrugs 2002;16:419-31.
14. Cafaro A, Titti F, Fracasso C, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001;6:2862-77.
15. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000;6:2469-73.
16. Klinman DM, Yi AK, Beaucage SL, Conover J, Kreig AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci U S A 1996;93: 2879-83.
17. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
18. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249-58.
19. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004;16:17-22.
20. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996;51:173-82.
21. Zhao Q, Yu D, Agrawal S. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett 1999;9:3453-8.
22. Zhao Q, Yu D, Agrawal S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett 2000;10: 1051-4.
23. Yu D, Zhao Q, Kandimalla ER, Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett 2000;10:2585-8.
24. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett 2001;11:2263-7.
25. Kandimalla ER, Yu D, Zhao Q, Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem 2001;9:807-13.
26. Yu D, Kandimalla ER, Cong Y, et al. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J Med Chem 2002;45:4540-8.
27. Yu D, Kandimalla D, Bhagat L, et al. "Immunomers" - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002;30:4460-9.
28. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001;98:9237-42.
29. Roberts TL, Sweet MJ, Hume DA, Stacey KJ. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 2005;174:605-8.
30. Kandimalla ER, Bhagat L, Zhu FG, et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A 2003;100:14303-8.
31. Li Y, Kandimalla ER, Yu D, Agrawal S. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. Int Immunopharmacol 2005;5: 981-91.
32. Kandimalla ER, Bhagat L, Li Y, et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A 2005;102: 6925-30.
33. Kandimalla ER, Bhagat L, Wang D, et al. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003;31:2393-400.
34. Yu D, Zhu FG, Bhagat L, et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun 2002;297:83-90.
35. Bhagat L, Zhu FG, Yu D, et al. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun 2003;300:853-61.
36. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 1999;96:13989-94.
37. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 2003;100:11636-41.
38. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003;54:194-205.
39. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279:19008-17.
40. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006;7:49-56.
41. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005;28: 886-92.
42. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1.
43. Pratesi G, Petrangolini G, Tortoreto M, et al. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65:6388-93.
44. Bauer S, Wagner H. Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol 2002;270:145-54.
45. Sohn WJ, Lee KW, Choi SY, et al. CpG-oligodeoxynucleotide protects immune cells from γ-irradiation-induced cell death. Mol Immunol 2006;43: 1163-71.
46. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19:3325-36.
47. Damiano V, Caputo R, Bianco R, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12:577-83.
48. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to Rlα subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 2002;21:73-80.